DOCSLIB.ORG

(12) Patent Application Publication (10) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub US 2002OO15735A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0015735A1 Hedden et al. (43) Pub. Date: Feb. 7, 2002 (54) SUSTAINED-RELEASE FORMULATION OF A of provisional application No. 60/181,635, filed on CYCLOOXYGENASE-2 INHIBITOR Feb. 10, 2000. Non-provisional of provisional appli cation No. 60/202,269, filed on May 5, 2000. (76) Inventors: David B. Hedden, Ann Arbor, MI (US); Sreekant Nadkarni, Gurnee, IL Publication Classification (US) (51) Int. Cl." ........................... A61K 9/14; A61K 31/44; Correspondence Address: A61K 31/415; A61K 31/135 Pharmacia Corporation (52) U.S. Cl. ......................... 424/488; 424/487; 514/406; Patent Department Central, 1820 514/349; 514/352; 514/646 P.O. BOX 5110 Chicago, IL 60680-5110 (US) (57) ABSTRACT (21) Appl. No.: 09/742,906 (22) Filed: Dec. 20, 2000 There is provided an orally deliverable pharmaceutical com position comprising a Selective cyclooxygenase-2 inhibitory Related U.S. Application Data drug of low water Solubility Such as celecoxib and a release extending polymer. The composition is useful in treatment (63) Non-provisional of provisional application No. of cyclooxygenase-2 mediated conditions and disorders by 60/171,738, filed on Dec. 22, 1999. Non-provisional once-a-day administration. Patent Application Publication Feb. 7, 2002 Sheet 1 of 5 US 2002/0015735 A1 % dissolution s... ', ... % is iss's S. O 2 4 6 8 10 12 14 16 18 Time (hours) -0-M4 --M5 -a-M6 -e-M7 --M8 -b-M9 -A-M10 -O-M11 Fig. 1 Patent Application Publication Feb. 7, 2002 Sheet 2 of 5 US 2002/0015735 A1 % dissolution 120 is: 100 O 2 4 6 8 10 12 14 16 18 Time (hours) -0-M12 -a-M13 --M14 -A-M15 -B-M16 -e-M17 -H-M18 -O-M19 -be-M2O --M21 Fig. 2 Patent Application Publication Feb. 7, 2002. Sheet 3 of 5 US 2002/0015735 A1 % dissolution 3& - s six. S- i. & ... Time (hours) -- S1 -- S2 -- S3 -- S4 -A-S5 -- S6 -e-S7 -o-S8 Fig. 3 Patent Application Publication Feb. 7, 2002 Sheet 4 of 5 US 2002/0015735A1 AssistsYESS ash 8 : : Time (hours) -A-Q5 (20-5-A) -e-Q6 (20-5-L) --Q7 (20-35-A) -O-O8 (20-35-L) Fig. 4 S.S.S.S. 8%. 8. gap". 2:2 . $33.33. Say s Time (hours) -A-Q11 (1,25) -A-Q12 (1,65) --Q13 (25,25) -HQ14 (25,65) -e-Q15 (13,45) -O-O 16 (1345) Fig. 5 Patent Application Publication Feb. 7, 2002 Sheet 5 of 5 US 2002/0015735 A1 - Time (hr) Fig. 6 -0-R tablet -HQ17 -A-Q18 US 2002/OO15735 A1 Feb. 7, 2002 SUSTAINED-RELEASE FORMULATION OFA 0004) Other compounds reported to have therapeutically CYCLOOXYGENASE-2 INHIBITOR and/or prophylactically useful selective COX-2 inhibitory 0001. This application claims priority of U.S. provisional effect are Substituted isoxazolyl benzeneSulfonamides as application Ser. No. 60/171,738 filed on Dec. 22, 1999, U.S. reported in U.S. Pat. No. 5,633,272 to Talley et al., including provisional application Ser. No. 60/181,635 filed on Feb. 10, the compound 4-5-methyl-3-phenylisoxazol-4-ylbenzene 2000, and U.S. provisional application Ser. No. 60/202,269 sulfonamide, also referred to herein as Valdecoxib (III). filed on May 5, 2000. FIELD OF THE INVENTION 0002 This invention relates to orally deliverable phar (III) maceutical compositions containing a Selective cyclooxyge nase-2 (COX-2) inhibitory drug as an active ingredient, to processes for preparing Such compositions, to methods of treatment of COX-2 mediated disorders comprising orally administering Such compositions to a Subject, and to use of Such compositions in manufacture of medicaments. BACKGROUND OF THE INVENTION 0003) Numerous compounds have been reported having therapeutically and/or prophylactically useful Selective COX-2 inhibitory effect, and having utility in treatment or prevention of specific COX-2 mediated disorders or of such disorders in general. Among Such compounds are a large number of Substituted pyrazolyl benzeneSulfonamides as 0005 Still other compounds reported to have therapeu reported in U.S. Pat. No. 5,760,068 to Talley et al., including tically and/or prophylactically useful selective COX-2 for example the compound 4-5-(4-methylphenyl)-3-(trif inhibitory effect are substituted (methylsulfonyl)phenyl luoromethyl)-1H-pyrazol-1-ylbenzenesulfonamide, also furanones as reported in U.S. Pat. No. 5,474,995 to Ducha referred to herein as celecoxib (I), and the compound rme et al., including the compound 3-phenyl-4-4-(methyl 4-5-(3-fluoro-4-methox yphenyl)-3-difluoromethyl)-1H sulfonyl)phenyl-5H-furan-2-one, also referred to herein as pyrazol-1-ylbenzenesulfonamide, also referred to herein as rofecoxib (IV). deracoxib (II). (IV) H2N O (I) S. HC (II) 0006 U.S. Pat. No. 5,981,576 to Belley et al. discloses a \ further series of (methylsulfonyl)phenyl furanones said to be useful as selective COX-2 inhibitory drugs, including 3-(1- cyclopropylmethoxy)-5,5-dimethyl-4-4-(methylsulfo 21 O nyl)phenyl)-5H-furan-2-one and 3-(1-cyclopropylethoxy)- NN CF2H 5,5-dimethyl-4-4-(methylsulfonyl)phenyl-5H-furan-2- S. OC. HC 0007 U.S. Pat. No. 5,861,419 to Dube et al. discloses No substituted pyridines said to be useful as selective COX-2 inhibitory drugs, including for example the compound 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridi nyl)pyridine (V). US 2002/OO15735 A1 Feb. 7, 2002 0012 Although the initial cost of Sustained-release deliv ery Systems may be greater than the costs associated with (V) conventional delivery Systems, average costs of extended treatment over time can be lower due to less frequent dosing, HN A” enhanced therapeutic benefit, reduced Side-effects, and a 4. reduction in the time required to dispense and administer the drug and monitor patient compliance. 21 C 0013 Many selective COX-2 inhibitory compounds, in particular those having low Solubility in water, including celecoxib, deracoxib, Valdecoxib and rofecoxib, possess s1S physical and chemical properties which make them poorly 2 amenable to Sustained-release dosage formulation. These HC N physical and chemical properties have presented practical difficulties in formulating longer-acting low Solubility Selec tive COX-2 inhibitory drugs for oral administration. 0008 European Patent Application No. 0 863 134 dis 0014 Illustratively, the formulation of celecoxib for closes the compound 2-(3,5-difluorophenyl)-3-4-(methyl effective Sustained-release oral administration to a Subject Sulfonyl)phenyl-2-cyclopenten-1-one said to be useful as a has hitherto been complicated by the unique physical, selective COX-2 inhibitory drug. chemical and pharmacological properties of celecoxib, par 0009 U.S. Pat. No. 6,034,256 discloses a series of ben ticularly its exceptionally low Solubility in aqueous media, Zopyrans said to be useful as selective COX-2 inhibitory its relatively high dose requirement, and patient-to-patient drugs, including the compound (S)-6,8-dichloro-2-(trifluo variability in its absorption. Drugs with extremely high or romethyl)-2H-1-benzopyran-3-carboxylic acid (VI). low aqueous Solubility are known to be difficult to incorpo rate into effective Sustained-release delivery Systems (Lie berman et al., ed. (1990) Pharmaceutical Dosage Forms: (VI) Tablets, 2nd ed., Vol. 3. Marcel Dekker, Inc., New York.) For example, a lower Solubility limit for Sustained-release prod ucts has been reported to be about 0.1 mg/ml (Fincher (1968) “Particle size of drugs and its relationship to absorp tion and activity”, J. Pharma. Sci., 57, 1825), whereas celecoxib has a Solubility of 5 ug/ml. Drugs having a relatively high oral dose requirement are also known to be poor candidates for Sustained-release Systems, in part Cl because inclusion of a Sufficient dose to provide prolonged therapeutic effect and of the release-Sustaining mechanism tend to result in an unacceptably large Volume of product 0010) A need for formulated compositions of selective (Lieberman et al., op. cit., p. 206). Finally, drugs that are COX-2 inhibitory drugs, in particular Sustained-release absorbed at a rate that varies significantly among treated compositions, exists. Sustained-release drug-delivery Sys Subjects have also been considered inferior candidates for tems can provide many benefits over conventional dosage Sustained-release Systems, in part because Such Systems forms. Generally, Sustained-release preparations provide a normally target a blood concentration of the drug not greatly longer period of therapeutic or prophylactic response com in excess of the threshold concentration for therapeutic pared to conventional rapid release dosage forms. For effectiveness, and Subjects showing relatively poor absorp example, in treatment of pain, Sustained-release formula tions are useful to maintain relatively constant analgesic tion can fail to reach that threshold concentration (Lieber drug release rates over a period of time, for example 12-24 man et al., op. cit., p. 207). hours, So that blood Serum concentration of the drug remains 0015 For these and other reasons, therefore, it would be at a therapeutically effective level for a longer duration than a difficult but much desired advance in the art to provide an is possible with a conventional dosage form of the drug. In effective Sustained-release formulation of a selective COX-2 addition, whereas Standard dosage forms typically exhibit inhibitory drug of low solubility, such as celecoxib. high initial drug release rates that can result in unnecessarily elevated blood Serum levels of the drug, Sustained-release 0016 A wide variety of controlled-release, slow-release, formulations can help maintain blood Serum levels of the programmed-release, timed-release, pulse-release, Sus drug at or slightly above the therapeutically effective thresh tained-release or extended-release technologies are known old.
Load more

Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Formulations Comprising Nanoparticulate Meloxicam
    (19) TZZ¥ZZ¥__T (11) EP 3 090 731 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.11.2016 Bulletin 2016/45 A61K 9/14 (2006.01) A61K 31/5415 (2006.01) (21) Application number: 16161176.9 (22) Date of filing: 27.02.2004 (84) Designated Contracting States: • Ryde, Tuula AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Malvern, PA Pennsylvania 19355 (US) HU IE IT LI LU MC NL PT RO SE SI SK TR • Pruitt, John, D. Suwanee, GA Georgia 30024 (US) (30) Priority: 03.03.2003 US 450705 P • Kline, Laura Harleysville, PA Pennsylvania 19438 (US) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (74) Representative: Wichmann, Hendrik 08006465.2 / 1 938 803 Wuesthoff & Wuesthoff 04785761.0 / 1 617 816 Patentanwälte PartG mbB Schweigerstraße 2 (71) Applicant: DV Technology LLC 81541 München (DE) Wilmington, Delaware 19801 (US) Remarks: (72) Inventors: This application was filed on 18-03-2016 as a • Cooper, Eugene, R. divisional application to the application mentioned Berwyn, PA Pennsylvania 19312 (US) under INID code 62. (54) FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM (57) The present invention is directed to composi- than about 2 microns; wherein said effective average par- tions comprising meloxicam. The stable meloxicam com- ticle size is different than the particle size of the nano- positions comprise (a) nanoparticulate particles of mel- particulate particles of meloxicam (a); and (c) at least one oxicam having an effective average particle size of less surface stabilizer. The invention relates also to uses of than about 2000 nm, (b) particles of meloxicam having the composition.
    [Show full text]
  • (19) 11 Patent Number: 6165500
    USOO6165500A United States Patent (19) 11 Patent Number: 6,165,500 Cevc (45) Date of Patent: *Dec. 26, 2000 54 PREPARATION FOR THE APPLICATION OF WO 88/07362 10/1988 WIPO. AGENTS IN MINI-DROPLETS OTHER PUBLICATIONS 75 Inventor: Gregor Cevc, Heimstetten, Germany V.M. Knepp et al., “Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Char 73 Assignee: Idea AG, Munich, Germany acteristics” on Journal of Controlled Release 12(1990) Mar., No. 1, Amsterdam, NL, pp. 25–30. (Exhibit A). * Notice: This patent issued on a continued pros- C.E. Price, “A Review of the Factors Influencing the Pen ecution application filed under 37 CFR etration of Pesticides Through Plant Leaves” on I.C.I. Ltd., 1.53(d), and is subject to the twenty year Plant Protection Division, Jealott's Hill Research Station, patent term provisions of 35 U.S.C. Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252. 154(a)(2). (Exhibit B). K. Karzel and R.K. Liedtke, “Mechanismen Transkutaner This patent is Subject to a terminal dis- Resorption” on Grandlagen/Basics, pp. 1487–1491. (Exhibit claimer. C). Michael Mezei, “Liposomes as a Skin Drug Delivery Sys 21 Appl. No.: 07/844,664 tem” 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp 345-358. (Exhibit E). 22 Filed: Apr. 8, 1992 Adrienn Gesztes and Michael Mazei, “Topical Anesthesia of 30 Foreign Application Priority Data the Skin by Liposome-Encapsulated Tetracaine” on Anesth Analg 1988; 67: pp 1079–81. (Exhibit F). Aug. 24, 1990 DE) Germany ............................... 40 26834 Harish M. Patel, "Liposomes as a Controlled-Release Sys Aug.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios Et Al
    US 20060078604A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios et al. (43) Pub. Date: Apr. 13, 2006 (54) TRANSDERMAL DRUG DELIVERY DEVICE Related U.S. Application Data INCLUDING AN OCCLUSIVE BACKING (60) Provisional application No. 60/616,861, filed on Oct. 8, 2004. (75) Inventors: David Kanios, Miami, FL (US); Juan A. Mantelle, Miami, FL (US); Viet Publication Classification Nguyen, Miami, FL (US) (51) Int. Cl. Correspondence Address: A 6LX 9/70 (2006.01) DCKSTEIN SHAPRO MORN & OSHINSKY (52) U.S. Cl. .............................................................. 424/449 LLP (57) ABSTRACT 2101 L Street, NW Washington, DC 20037 (US) A transdermal drug delivery system for the topical applica tion of one or more active agents contained in one or more (73) Assignee: Noven Pharmaceuticals, Inc. polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can (21) Appl. No.: 11/245,180 control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmis (22) Filed: Oct. 7, 2005 sion rate of the polymeric backing layer. Patent Application Publication Apr. 13, 2006 Sheet 1 of 2 US 2006/0078604 A1 Fis ZZZZZZZZZZZZZZZZZZZ :::::::::::::::::::::::::::::::: Patent Application Publication Apr. 13, 2006 Sheet 2 of 2 US 2006/0078604 A1 3. s s 3. a 3 : 8 g US 2006/0078604 A1 Apr. 13, 2006 TRANSIDERMAL DRUG DELVERY DEVICE 0008. In the “classic' reservoir-type device, the active INCLUDING AN OCCLUSIVE BACKING agent is typically dissolved or dispersed in a carrier to yield a non-finite carrier form, Such as, for example, a fluid or gel.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0013357 A1 Nadkarni Et Al
    US 2002001.3357A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0013357 A1 Nadkarni et al. (43) Pub. Date: Jan. 31, 2002 (54) VALDECOXIB COMPOSITIONS 60/169,856, filed on Dec. 9, 1999. Non-provisional of provisional application No. 60/181,635, filed on Feb. (76) Inventors: Sreekant Nadkarni, Gurnee, IL (US); 10, 2000. Non-provisional of provisional application Mark J. Kontny, Libertyville, IL (US) No. 60/202,269, filed on May 5, 2000. Correspondence Address: Publication Classification Pharmacia Corporation Patent Department Central, 1820 (51) Int. Cl." .......................... A61K 31/415; A61 K 9/22 P.O. BOX 5110 (52) U.S. Cl. ............................................ 514/406; 424/468 Chicago, IL 60680-5110 (US) (21) Appl. No.: 09/731,349 (57) ABSTRACT (22) Filed: Dec. 6, 2000 Pharmaceutical compositions are provided comprising par ticulate Valdecoxib in an amount of about 1 mg to about 100 Related U.S. Application Data mg and one or more pharmaceutically acceptable excipients. The compositions are useful in treatment or prophylaxis of (63) Non-provisional of provisional application No. cyclooxygenase-2 mediated conditions and disorders. Patent Application Publication Jan. 31, 2002 Sheet 1 of 3 US 2002/0013357 A1 Micronizing Valdecoxib (Pin mill) Primary diluent Mixing Secondary diluent (Planetary mixer) Binding agent Wet granulation (Planetary mixer) Water Drying (Owen) Dry sizing (Comil) Blending Disintegrant (V-blender) Blending Lubricant (W-blender) Tableting (Rotary press) Fig. 1 Patent Application Publication Jan. 31, 2002. Sheet 2 of 3 US 2002/0013357 A1 Micronizing Valdecoxib (Pin mill) Primary diluent Mixing Binding agent Secondary diluent Disintegrant (intragranular) (High shear mixer) (intragranular) Wet granulation (High shear mixer) Water Drying (Fluid bed drier) Dry sizing (Fitzmill) Secondary diluent Blending Disintegrant (extragranular) (V-blender) (extragranular) Blending Lubricant (V-blender) Tableting (Rotary press) Fig.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Current Pharma Research ISSN-2230-7842 CODEN-CPRUE6
    Curr. Pharm. Res. 2019, 409, 72-80 Current Pharma Research ISSN-2230-7842 CODEN-CPRUE6 www.jcpronline.in/ Research Article Theme- New horizons in chemical sciences. Guest Editor- R.P. Pawar Monosodium Glutamate: An Efficient and Green Catalyst for the Synthesis of Bis(pyrazol- 5-ol)s Under Solvent Free Condition. Manoj P. Palve*,1, Jaysing M. Dinore1, Rajendra P. Pawar2, Rajita D. Ingle1 1Department of Chemistry, Indraraj Arts, Commerce and Science College, Sillod, Maharashtra, India. 2Department of Chemistry, Deogiri College, Aurangabad, Maharashtra, India. Received 13 March 2019; received in revised form 16 August 2019; accepted 25 August 2019 *Corresponding author E-mail address: [email protected] ABSTRACT An environmentally benign, facile and an efficient direct simple approach to construct the library of bis(pyrazol-5-ol)s derivatives has been developed by using Monosodium Glutamate (MSG) as a green catalyst under solvent free condition. This method proceeds through the tandem Knoevenagel-Michael reaction. The present synthetic route is a green protocol offering several advantages, such as high yield of products, shorter reaction time, mild reaction conditions, minimizing chemical waste and exclusion of environmentally hazardous solvent make this protocol widely acceptable. KEYWORDS Aromatic aldehyde, Ethyl acetoacetate, Phenyl hydrazine, Monosodium Glutamate. 72 Curr. Pharm. Res. 2019, 409, 72-80 1. INTRODUCTION Heterocyclic compounds are the important sorts of organic compounds, which are widely used in medicinal chemistry. The drugs which contain the core of heterocycles in its skeletons shows various biological activities such as antifungal activity, anti-inflammation, anti-bacterial, antioxidants, anticonvulsant, ant allergic, herbicidal activity and anticancer etc.[1] Medicinal chemistry occupies an important position to establish a relationship between chemical structure and pharmacological activity.
    [Show full text]
  • (12) Patent Application Publication (10) Pub
    US 2004O156872A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0156872 A1 Bosch et al. (43) Pub. Date: Aug. 12, 2004 (54) NOVEL NMESULIDE COMPOSITIONS application No. 09/572,961, filed on May 18, 2000, now Pat. No. 6,316,029. (75) Inventors: H. William Bosch, Bryn Mawr, PA (US); Christian F. Wertz, Brookhaven, Publication Classification PA (US) (51) Int. Cl. ............................ A61K 9/14; A61K 9/00 Correspondence Address: FOLEY AND LARDNER (52) U.S. Cl. ............................................ 424/400; 424/489 SUTE 500 3000 KSTREET NW WASHINGTON, DC 20007 (US) (57) ABSTRACT (73) Assignee: Elan Pharma International Ltd. The present invention provides nanoparticulate nimeSulide (21) Appl. No.: 10/697,703 compositions. The compositions preferably comprise nime (22) Filed: Oct. 31, 2003 Sulide and at least one Surface Stabilizer adsorbed on or asSociated with the Surface of the nimeSulide particles. The Related U.S. Application Data nanoparticulate nimeSulide particles preferably have an effective average particle size of less than about 2000 nm. (63) Continuation-in-part of application No. 10/276,400, The invention also provides methods of making and using filed on Jan. 15, 2003, which is a continuation of nanoparticulate nimeSulide compositions. US 2004/O156872 A1 Aug. 12, 2004 NOVEL NMESULIDE COMPOSITIONS tion;' U.S. Pat. Nos. 5,399,363 and 5,494,683, both for “Surface Modified Anticancer Nanoparticles; U.S. Pat. No. RELATED APPLICATIONS 5,401,492 for “Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents,” 0001. This application is a continuation-in-part of U.S. U.S. Pat. No.
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]